Rikke Hahn Kofoed

Rikke Hahn Kofoed

Auto-generated profile, based on publicly available information

Rikke Hahn Kofoed

Biological Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2018 in EMBO Reports
Verified
Journal Article
Open access
PDF file
CBCristine Betzer
Cristine Betzer
LLLouise Berkhoudt Lassen
Louise Berkhoudt Lassen
Anders OlsenAnders Olsen
Anders Olsen
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
LRLasse Reimer
Lasse Reimer
PJPoul Henning Jensen
Poul Henning Jensen
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

26 April 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLouise Berkhoudt Lassen
Louise Berkhoudt Lassen
EGEmil Gregersen
Emil Gregersen
AIAnne Kathrine Isager
Anne Kathrine Isager
CBCristine Betzer
Cristine Betzer
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
PJPoul Henning Jensen
Poul Henning Jensen
Soluble aggregates of α-synuclein, so-called oligomers, are hypothesized to act as neurotoxic species in Parkinson’s disease, Lewy body dementia and multiple systems atrophy, but specific tools to detect these aggregated species are only slowly appearing. We have developed an α-synuclein oligomer ELISA that allows us to detect and compare α-synuclein oligomer levels in different in vivo and in vitro experiments. The ELISA is based on commercially available antibodies and the epitope of the capture antibody MJF14-6-4-2 is folding- and aggregate-dependent and not present on monomers.

6 October 2022 in Journal of Controlled Release
Verified
Journal Article
Open access
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
CDChinaza Lilian Dibia
Chinaza Lilian Dibia
KNKate Noseworthy
Kate Noseworthy
KXKristiana Xhima
Kristiana Xhima
NVNathalie Vacaresse
Nathalie Vacaresse
IAIsabelle Aubert
Isabelle Aubert
Focused ultrasound combined with intravenously injected microbubbles (FUS) is known to non-invasively, locally, and transiently increase the permeability of the blood-brain barrier (BBB). A promising approach for non-invasive gene delivery to the brain is to administer recombinant adeno-associated viruses (AAVs) intravenously and allow them to cross the BBB at precise FUS-targeted brain regions. FUS-AAV delivery has been achieved in animal models; however, the key elements influencing, guiding, and monitoring the success of FUS-AAV delivery to the brain remain largely unknown. We systematically compared the ability of AAV1, AAV2, AAV5, AAV8, AAV9, and AAVrg to enter four specific brain regions and transduce two main cell types: neurons and astrocytes. Our results demonstrate that the AAV serotype, the extent of FUS-induced BBB permeability, and the intrinsic properties of the targeted brain tissue influence the observed biodistribution, diffusion and transduction of AAV to cells of the cerebrovasculature and brain parenchyma. Non-invasive contrast-enhanced MR imaging was found to predict the efficacy of FUS-AAV delivery. Notably, we also found that AAVs with high biodistribution to peripheral organs result in low gene delivery to the brain when combined with FUS. Gene delivery by AAV1, AAV2, AAV5, AAV8 and AAV9 was highly and selectively localized to FUS-targeted brain areas. To obtain non-invasive gene delivery to multiple brain regions with one area of FUS-BBB modulation, we combined a modified AAV2 vector harboring enhanced retrograde transport properties (AAVrg) with FUS-mediated brain delivery. This allowed for gene delivery from the FUS-targeted site to multiple connected brain regions. This study demonstrates that MR imaging can be used as a non-invasive indication of AAV delivery to the brain, and that the properties of AAV serotypes influence the efficacy of gene delivery to the brain with FUS. AAVs that have minimal peripheral biodistribution are ideal candidates for enhanced, and perhaps exclusive with future serotypes, delivery to the brain with FUS. The characterization of parameters influencing FUS-AAV delivery to the brain are critical to the design of safe and efficient gene therapies, from preclinical studies to future clinical applications.

1 July 2018 in Neurobiology of Disease
Verified
Journal Article
Closed access
LRLasse Reimer
Lasse Reimer
LVLouise Buur Vesterager
Louise Buur Vesterager
CBCristine Betzer
Cristine Betzer
JZJin Zheng
Jin Zheng
LNLærke Dalsgaard Nielsen
Lærke Dalsgaard Nielsen
PJPoul Henning Jensen
Poul Henning Jensen

11 January 2024 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
IAIsabelle Aubert
Isabelle Aubert

17 December 2021 in Brain
Verified
Journal Article
Open access
PDF file
KXKristiana Xhima
Kristiana Xhima
KMKelly Markham-Coultes
Kelly Markham-Coultes
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
HSH. Uri Saragovi
H. Uri Saragovi
KHKullervo Hynynen
Kullervo Hynynen
IAIsabelle Aubert
Isabelle Aubert
Early degeneration of basal forebrain cholinergic neurons contributes substantially to cognitive decline in Alzheimer’s disease. Evidence from preclinical models of neuronal injury and aging support a pivotal role for nerve growth factor (NGF) in neuroprotection, resilience, and cognitive function. However, whether NGF can provide therapeutic benefit in the presence of Alzheimer’s disease-related pathologies still unresolved. Perturbations in the NGF signalling system in Alzheimer’s disease may render neurons unable to benefit from NGF administration. Additionally, challenges related to brain delivery remain for clinical translation of NGF-based therapies in Alzheimer’s disease. To be safe and efficient, NGF-related agents should stimulate the NGF receptor, tropomyosin receptor kinase A (TrkA), avoid activation through the p75 neurotrophin receptor (p75NTR), and be delivered non-invasively to targeted brain areas using real-time monitoring. We addressed these limitations using MRI-guided focused ultrasound (MRIgFUS) to increase blood–brain barrier permeability locally and transiently, allowing an intravenously administered TrkA agonist that does not activate p75NTR, termed D3, to enter targeted brain areas. Here, we report the therapeutic potential of selective TrkA activation in a transgenic mouse model that recapitulates numerous Alzheimer’s disease-associated pathologies. Repeated MRIgFUS-mediated delivery of D3 (D3/FUS) improved cognitive function in the TgCRND8 model of Alzheimer’s disease. Mechanistically, D3/FUS treatment effectively attenuated cholinergic degeneration and promoted functional recovery. D3/FUS treatment also resulted in widespread reduction of brain amyloid pathology and dystrophic neurites surrounding amyloid plaques. Furthermore, D3/FUS markedly enhanced hippocampal neurogenesis in TgCRND8 mice, implicating TrkA agonism as a novel therapeutic target to promote neurogenesis in the context of Alzheimer’s disease-related pathology. Thus, this study provides evidence that selective TrkA agonism confers neuroprotection to effectively counteract Alzheimer’s disease-related vulnerability. Recent clinical trials demonstrate that non-invasive blood–brain barrier modulation using MRIgFUS is safe, feasible and reversible in Alzheimer’s disease patients. TrkA receptor agonists coupled with MRIgFUS delivery constitute a promising disease-modifying strategy to foster brain health and counteract cognitive decline in Alzheimer’s disease.